| Literature DB >> 27267108 |
Cathrine Elgaard Jensen1, Martin Bach Jensen2, Allan Riis2, Karin Dam Petersen1.
Abstract
OBJECTIVE: The primary aim is to identify, summarise and quality assess the available literature on the cost-effectiveness of implementing low back pain guidelines in primary care. The secondary aim is to assess the transferability of the results to determine whether the identified studies can be included in a comparison with a Danish implementation study to establish which strategy procures most value for money.Entities:
Keywords: Guideline implementation; HEALTH ECONOMICS; Low back pain; Primary health care; Transferability
Mesh:
Year: 2016 PMID: 27267108 PMCID: PMC4908862 DOI: 10.1136/bmjopen-2016-011042
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of study selection.9 LBP, low back pain; RCT, randomised controlled trial.
Characteristics of the included studies
| Study | Mortimer | Becker | Hoeijenbos |
|---|---|---|---|
| Country | Australia | Germany | The Netherlands |
| Economic evaluation | Cost-effectiveness | Cost-effectiveness | Cost-utility |
| Study design | Cluster randomised clinical trial | Cluster randomised clinical trial | Cluster randomised clinical trial* |
| Study population | NA† | LBP, age >20, understand German | LBP, understand Dutch |
| Participants | NA† | 1322 patients | 483 patients |
| Intervention | Multifaceted and theory-based implementation strategy (IMPLEMENT) vs dissemination. | Physician education vs dissemination | Active implementation strategy vs dissemination. |
| Perspective | Health sector | Societal | Societal |
| Time horizon | 12 month follow-up | 12 month follow-up | 12 month follow-up |
| Effectiveness measures |
Number of X-ray referrals†‡ Adherence to guideline in simulated practices |
Hannover Functional Ability Questionnaire‡ Physical activity Days in pain Days of sick leave Quality of life |
Quality of life |
| ICER | IMPLEMENT dominates standard dissemination.§ | Both intervention groups dominate standard dissemination.§ | Not calculated. No significant differences between active strategy and dissemination were found in either costs or effects. |
| Sensitivity analysis | PSA | PSA | None |
| Author conclusion | Substantial additional upfront investment, which may not result in better outcomes sufficient to render active implementation cost-effective. | Both interventions show superiority by trend. | Active strategy appears not to be cost-effective. |
*Derived from two articles by Bekkering et al.15 16
†Failure of patient recruitment necessitated a departure from the originally proposed analyses.
‡Primary outcome.
§Valid for the primary outcome.
ICER, incremental cost-effectiveness ratio; LBP, low back pain; NA, not applicable; PSA, probabilistic sensitivity analysis.
Quality assessment of the included studies using the Consensus Health Economic Criteria (CHEC) list
| Item | Mortimer | Becker | Hoeijenbos |
|---|---|---|---|
| 1. Is the study population clearly described? | Yes | Yes | No |
| 2. Are competing alternatives clearly described? | Yes | Yes | Yes |
| 3. Is a well-defined research question posed in answerable form? | Yes | Yes | No |
| 4. Is the economic study design appropriate to the stated objective? | Yes | Yes | Yes |
| 5. Is the chosen time horizon appropriate to include relevant costs and consequences? | Yes | Yes | Yes |
| 6. Is the actual perspective chosen appropriate? | No | Yes | Yes |
| 7. Are all important and relevant costs for each alternative identified? | Yes | Yes* | Yes |
| 8. Are all costs measured appropriately in physical units? | Yes | Yes* | Yes |
| 9. Are costs valued appropriately? | Yes | No* | No |
| 10. Are all important and relevant outcomes for each alternative identified? | No | No | No |
| 11. Are all outcomes measured appropriately? | No | No | No |
| 12. Are outcomes valued appropriately? | No | Yes | Yes |
| 13. Is an incremental analysis of costs and outcomes of alternatives performed? | Yes | Yes | No |
| 14. Are all future costs and outcomes discounted appropriately? | No | Yes | Yes |
| 15. Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis? | No | No | No |
| 16. Do the conclusions follow from the data reported? | No | No | Yes |
| 17. Does the study discuss the generalizability of the results to other settings and patient/client groups? | Yes | Yes | Yes |
| 18. Does the article indicate that there is no potential conflict of interest of study researcher(s) and funder(s)? | Yes | Yes | No |
| 19. Are ethical and distributional issues discussed appropriately? | Yes | No | No |
| Total (%) | 63 | 68 | 53 |
*Derived from by Becker et al.18
Transferability of Becker et al13 to a Danish setting
| Transferability factor | Estimated relevance | Estimated correspondence between the study country and the decision country | Estimation of CER of decision country based on CER of study country |
|---|---|---|---|
| Perspective | Very high | Very high | Unbiased |
| Discount rate | NA* | NA | Unbiased |
| Medical cost approach | Medium | Very high | Unbiased |
| Productivity cost approach | High | Very high | Unbiased |
| Absolute and relative prices in healthcare | High | Unclear† | Too high or too low |
| Practice variation | Medium | High | Unbiased |
| Technology availability | Low | High | Unbiased |
| Disease incidence/prevalence | Low | High | Unbiased |
| Case mix | Low | Very high | Unbiased |
| Life expectancy | NA | NA | Unbiased |
| Health status preferences | High | Low | Too high or too low |
| Acceptance, compliance, incentives to patients | Low | High | Unbiased |
| Productivity and work-loss time | Very high | Medium | Too high or too low |
| Disease spread | NA | NA | Unbiased |
*Time horizon of 12 months.
†Level of detail presented is not sufficient to estimate correspondence.18
CER, cost-effectiveness ratio; NA, not applicable.
Transferability of Hoeijenbos et al14 to a Danish setting
| Transferability factor | Estimated relevance | Estimated correspondence between the study country and the decision country | Estimation of CER of the study country compared with the decision country is: |
|---|---|---|---|
| Perspective | Very high | Very high | Unbiased |
| Discount rate | NA* | NA | Unbiased |
| Medical cost approach | Medium | Very high | Unbiased |
| Productivity cost approach | Very high | Low | Too low |
| Absolute and relative prices in healthcare | High | High | Unbiased |
| Practice variation | Medium | High | Unbiased |
| Technology availability | Low | High | Unbiased |
| Disease incidence/prevalence | Low | High | Unbiased |
| Case mix | Low | Very high | Unbiased |
| Life expectancy | NA | NA | Unbiased |
| Health status preferences | Medium | High | Unbiased |
| Acceptance, compliance, incentives to patients | Low | High | Unbiased |
| Productivity and work-loss time | Very high | Medium | Too high or too low |
| Disease spread | NA | NA | Unbiased |
*Time horizon of 12 months.
CER, cost-effectiveness ratio; NA, not applicable.